Abstract
Dendritic cells (DC) are extremely potent antigen-presenting cells, which can prime both naïve CD4+ and CD8+ T lymphocytes. In their immature state, DC continuously sample and process antigens from the surrounding environment, but only mature DC express sufficient levels of costimulatory molecules to activate naïve T cells. DC present in tumors are functionally immature owing to the immunosuppressive actions of tumor-derived factors and regulatory T cells, and such immature DC promote immune tolerance to the tumor. Recent studies from animal models suggest that Toll-like receptor (TLR) agonists such as CpG can reverse the tolerogenic state of tumoral DC. Strategies that allow DC to gain access to both tumor antigens and TLR agonists, in situ, can overcome tumor tolerance leading to the induction of potent systemic antitumor immunity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Banchereau, J. and Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245–252.
Banchereau, J., Briere, F., Caux, C., et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767–811.
Gabrilovich, D., Ishida, T., Oyama, T., et al. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150–4166.
Bell, D., Chomarat, P., Broyles, D., et al. (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417–1426.
Vermi, W., Bonecchi, R., Facchetti, F., et al. (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200, 255–268.
Engleman, E. G., Brody, J., and Soares, L. (2004) Using signaling pathways to overcome immune tolerance to tumors. Sci. STKE 2004, 28.
Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263–274.
Pasare, C. and Medzhitov, R. (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033–1036.
Yang, Y., Huang, C. T., Huang, X., and Pardoll, D. M. (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5, 508–515.
Medzhitov, R. (2001) Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145.
Hsu, F. J., Benike, C., Fagnoni, F., et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52–58.
Nestle, F. O., Alijagic, S., Gilliet, M., et al. (1998) Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328–332.
Fong, L., Hou, Y., Rivas, A., et al. (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809–8814.
Fong, L. and Engleman, E. G. (2000) Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245–273.
Merad, M., Sugie, T., Engleman, E. G., and Fong, L. (2002) In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99, 1676–1682.
Furumoto, K., Soares, L., Engleman, E. G., and Merad, M. (2004) Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774–783.
Okano, F., Merad, M., Furumoto, K., and Engleman, E. G. (2005) In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J. Immunol. 174, 2645–2652.
Maraskovsky, E., Brasel, K., Teepe, M., et al. (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953–1962.
Gilboa, E. (1999) The makings of a tumor rejection antigen. Immunity 11, 263–270.
Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709–760.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Mende, I., Engleman, E.G. (2007). Breaking Self-Tolerance to Tumor-Associated Antigens by In Vivo Manipulation of Dendritic Cells. In: Fairchild, P.J. (eds) Immunological Tolerance. Methods in Molecular Biology™, vol 380. Humana Press. https://doi.org/10.1007/978-1-59745-395-0_29
Download citation
DOI: https://doi.org/10.1007/978-1-59745-395-0_29
Publisher Name: Humana Press
Print ISBN: 978-1-58829-652-8
Online ISBN: 978-1-59745-395-0
eBook Packages: Springer Protocols